SECURITIES AND EXCHANGE COMMISSION
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
HALOZYME THERAPEUTICS, INC.
|(State of incorporation)||(I.R.S. Employer Identification No.)|
|11588 Sorrento Valley Road, Suite 17|
|San Diego, California||92121|
|(Address of principal executive offices)||(Zip Code)|
Securities to be registered pursuant to Section 12(b) of the Act:
|Title of each class
to be so registered
|Name of each exchange on which
each class is to be registered
|Common Stock, $0.001 Par Value||American Stock Exchange|
If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. [X]
If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. [ ]
Securities Act registration statement file number to which this form
Securities to be registered pursuant to Section 12(g) of the Act:
|Item 1. Description of Registrants Securities to be Registered|
|Item 2. Exhibits|
Item 1. Description of Registrants Securities to be Registered
The capital stock of Halozyme Therapeutics, Inc. (the Company or Registrant) to be registered on the American Stock Exchange (the Exchange) is the Registrants Common Stock with a par value of $0.001 per share.
The description of the Registrations Common Stock contained in the Companys latest prospectus dated July 23, 2004, filed as a part of Registration Statement on Form SB-2/A, File No. 333-114776, is incorporated by reference. An index appears on the outside back cover page of the prospectus.
Item 2. Exhibits
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
Date: October 27, 2004
|Halozyme Therapeutics, Inc.|
|By:||/s/ Jonathan E. Lim
Jonathan E. Lim, M.D.
President and Chief Executive Officer